Biopharmaceutical manufacturers face a critical decision: prioritize speed or quality in two-step chromatography purification processes. While the desire for both is strong, the reality is that each choice carries inherent tradeoffs that can impact purity, stability, toxicity, processing times, and costs.
A multinational research team has developed an analytical model aimed at navigating these complexities. According to Dr. Yasemin Limon of Bilkent University, this model allows biomanufacturers to manage speed-quality tradeoffs and stage-specific lead-time constraints effectively. By utilizing queueing network theory, the model correlates intervention efforts with their effects on stability timeframes and the likelihood of quality enhancement.
The researchers categorize purification optimization into two types: Type I interventions enhance batch quality without extending processing times, while Type II interventions improve both purity and processing durations. Their findings indicate that optimal intervention strategies vary with costs and processing times, emphasizing the interdependence of decisions made at each chromatography step. This model serves as a decision-making tool, enabling manufacturers to optimize operations while minimizing risks associated with prolonged wait times that could compromise product integrity.
Open the full market picture for your next decision →
